FDA Extends The Review Of Avastin For Breast Cancer By Another 3 Months.

Avastin, a cancer fighting drug is under examination and FDA has announced today that the review will be extended by another 90 days. The review is to decide if the drug should be used in treatment of breast Cancer. The expensive drug seem to have not worked very well on breast cancer patients.
Avastin was approved by FDA in 2008 for breast cancer patients based on a trial. As a condition of approval, Roche, parent company of Genentech was required to conduct follow-up studies to demonstrate further the benefits of adding Avastin to conventional chemotherapy.In July an FDA advisory committee recommended the FDA, to revoke the Avastin's approval for breast cancer.

If the FDA revokes the approval, it's believed insurance companies will stop paying for this drug, which could cost more than $8,000 a month. Only the very rich will be able to afford the treatment.